Chardan analyst Geulah Livshits raised the firm’s price target on Krystal Biotech to $133 from $130 and keeps a Buy rating on the shares. Following Q3 results, Livshits noted that Krystal now expects to resume patient dosing with topical KB105 in the next cohort of the Phase II in TMG1-mediated ARCI in early 2023. With respect to the preclinical pipeline, the analyst noted a slight softening of guidance for filing an IND for KB105 in Netherton syndrome now in 1H23 from 2H22.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on KRYS:
- Krystal Biotech price target raised to $119 from $107 at H.C. Wainwright
- Krystal Biotech Announces Third Quarter 2022 Financial Results and Operational Highlights
- Krystal Biotech reports Q3 EPS ($1.17), consensus ($1.22)
- Krystal Biotech to Present at Chardan’s 6th Annual Genetic Medicines Conference
- Krystal Biotech Receives Positive Opinion from EMA Pediatric Committee on the Pediatric Investigation Plan for B-VEC for the treatment of Dystrophic Epidermolysis Bullosa
